User:Mr. Ibrahem/Dalbavancin

Dalbavancin, sold under the trade names Dalvance among others, is an antibiotic used to treat bacterial skin infections, including those caused by methicillin-resistant Staphylococcus aureus (MRSA). It is give by injection into a vein either as a single dose or two doses one week apart.

Common side effects include nausea, diarrhea, rash, and headache. Other side effects may include antibiotic associated colitis, constipation, and low white blood cells. It is unclear if use is safe in pregnancy or breastfeeding. It is in the lipoglycopeptide class of medications, along with vancomycin.

Dalbavancin was approved for medical use in the United States in 2014 and Europe in 2015. In the United States the a course of medication costs about 4,800 USD as of 2021. In the United Kingdom this amount costs the NHS about £1,700.